🇺🇸 FDA
Pipeline program

CAM2029 (octreotide subcutaneous depot), CAM2029 (octreotide subcutaneous depot)

HS-19-647

Phase 3 small_molecule active

Quick answer

CAM2029 (octreotide subcutaneous depot), CAM2029 (octreotide subcutaneous depot) for Acromegaly is a Phase 3 program (small_molecule) at Camurus AB with 1 ClinicalTrials.gov record(s).

Program details

Company
Camurus AB
Indication
Acromegaly
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials